November 12, 2020
Medicare to cover monoclonal antibody COVID-19 treatments
Editor's Note
The Centers for Medicare and Medicaid Services (CMS) on November 10 announced that Medicare will cover out-of-pocket costs for monoclonal antibody drugs for COVID-19 during the public health emergency.
The agency’s coverage includes Eli Lilly’s bamlanivimab, which recently received an emergency use authorization from the Food and Drug Administration.
Medicare won’t pay for monoclonal antibody products that providers receive for free, but it will pay for the infusion.
Free Daily News
- Trump vs. Harris: Key differences in healthcare proposals for Medicaid, Medicare, private insurance, abortion
- Updated AAMI standard addresses chemical sterilization safety, compliance
- Study: Stool tests show promise in reducing colonoscopies for post-polypectomy colorectal cancer surveillance
- Healthcare employment up in October
- Save the date for OR Manager Conference 2025
- Session: Staff resilience during extended downtime
- Session: Managing difficult conversations—How to respond effectively to your team
- Closing Keynote: The fire within—The art of bold self leadership
- Session: The case for disrupting, revolutionizing OR, SPD education
- Session: What talented nurses want from potential employers
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement